Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Endocr Relat Cancer ; 6(2): 303-6, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10731123

RESUMEN

During puberty, estrogen causes breast maturation and growth of the uterine lining in girls, and accelerates linear growth and bone maturation in both boys and girls. Decreasing the biosynthesis of estrogen can attenuate these processes. In 12 girls with the McCune-Albright syndrome (MAS), in which precocious puberty is due to production of estrogen from ovarian cysts, testolactone (40 mg/kg per day) decreased the volume of ovarian cysts, the frequency of menses, and the rates of growth and bone maturation, for periods of 1-4 years. In a 6-month pilot study of 12 children (eight boys; four girls) with congenital adrenal hyperplasia, testolactone, in combination with an antiandrogen (flutamide), a mineralocorticoid (fludrocortisone acetate, Florinef), and a reduced glucocorticoid dose, improved the control of growth and bone maturation compared with conventional therapy. In a 6-year study of 10 boys with familial male precocious puberty, testolactone, in combination with an antiandrogen (spironolactone), decreased rates of growth and bone maturation, and increased predicted adult height. All patients who developed evidence for gonadotropin-dependent puberty were also treated with a GnRH analog. Testolactone had no important adverse effects in any group of patients, although the need for a four-times-daily dosing schedule made compliance difficult for many families. We conclude that suppressing of estrogen with testolactone was effective therapy, and that more potent and specific inhibitors of aromatase could further improve the treatment of these disorders.


Asunto(s)
Inhibidores de la Aromatasa , Inhibidores Enzimáticos/uso terapéutico , Pubertad Precoz/tratamiento farmacológico , Testolactona/uso terapéutico , Hiperplasia Suprarrenal Congénita/fisiopatología , Antineoplásicos Hormonales/uso terapéutico , Estrógenos/metabolismo , Femenino , Displasia Fibrosa Poliostótica/fisiopatología , Humanos , Masculino , Pubertad Precoz/genética , Pubertad Precoz/metabolismo
2.
J Clin Endocrinol Metab ; 84(1): 175-8, 1999 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9920079

RESUMEN

Short term treatment with spironolactone, testolactone, and, after the onset of central puberty, deslorelin can normalize the rate of growth and bone maturation in boys with familial male-limited precocious puberty. To test the hypothesis that this treatment can achieve long term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (change in bone age/change in chronological age), and predicted adult height of 10 boys who were treated with spironolactone (5.7 mg/kg x day) and testolactone (40 mg/kg x day) for at least 6 yr. Deslorelin (4 microg/kg x day) treatment was initiated 2.6 +/- 1.3 yr after beginning spironolactone and testolactone treatment. The growth rate normalized within 1 yr of starting treatment and remained normal during the next 5 yr of treatment (P < 0.001). The rate of bone maturation normalized during the second year of treatment and remained normal thereafter (P < 0.001). Predicted height increased from 160.7 +/- 14.7 centimeters at baseline to 173.6 +/- 10.1 centimeters after 6 yr of treatment (P < 0.05 during the fourth through the sixth year of treatment compared to baseline). We conclude that long term treatment with spironolactone, testolactone, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. The ultimate effect of this approach on adult height will require further study.


Asunto(s)
Hormona Liberadora de Gonadotropina/análogos & derivados , Pubertad Precoz/tratamiento farmacológico , Espironolactona/administración & dosificación , Testolactona/administración & dosificación , Adolescente , Desarrollo Óseo/efectos de los fármacos , Niño , Preescolar , Hormona Liberadora de Gonadotropina/administración & dosificación , Crecimiento/efectos de los fármacos , Humanos , Masculino , Pubertad Precoz/genética , Pubertad Precoz/fisiopatología , Espironolactona/efectos adversos , Testolactona/efectos adversos , Testosterona/sangre , Pamoato de Triptorelina/análogos & derivados
3.
Front Biosci ; 5: D343-52, 2000 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-10704433

RESUMEN

Human male sexual development is regulated by chorionic gonadotropin (CG) and luteinizing hormone (LH). Aberrant sexual development caused by both activating and inactivating mutations of the human luteinizing hormone receptor (LHR) have been described. All known activating mutations of the LHR are missense mutations caused by single base substitution. The most common activating mutation is the replacement of Asp-578 by Gly due to the substitution of A by G at nucleotide position 1733. All activating mutations are present in exon 11 which encodes the transmembrane domain of the receptor. Constitutive activity of the LHR causes LH releasing hormone-independent precocious puberty in boys and the autosomal dominant disorder familial male-limited precocious puberty (FMPP). Both germline and somatic activating mutations of the LHR have been found in patients with testicular tumors. Activating mutations have no effect on females. The molecular genetics of the inactivating mutations of the LHR are more variable and include single base substitution, partial gene deletion, and insertion. These mutations are not localized and are present in both the extracellular and transmembrane domain of the receptor. Inactivation of the LHR gives rise to the autosomal recessive disorder Leydig cell hypoplasia (LCH) and male hypogonadism or male pseudohermaphroditism. Severity of the clinical phenotype in LCH patients correlates with the amount of residual activity of the mutated receptor. Females are less affected by inactivating mutation of the LHR. Symptoms caused by homozygous inactivating mutation of the LHR include polycystic ovaries and primary amenorrhea.


Asunto(s)
Trastornos del Desarrollo Sexual/genética , Receptores de HL/genética , Neoplasias Testiculares/genética , Femenino , Humanos , Masculino , Mutación
4.
J Am Acad Child Adolesc Psychiatry ; 40(3): 373-6, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11288780

RESUMEN

Familial male precocious puberty is a form of precocious puberty resulting from an activating mutation of the luteinizing hormone receptor. Behavior problems are associated with the early onset of puberty. In this case, sexual hyperactivity was treated with psychostimulants. Implications for the effectiveness of methylphenidate in reducing sexual hyperactivity with and without familial male precocious puberty are discussed, and testable hypotheses are proposed for the effects of stimulants on sexual behavior in adolescents.


Asunto(s)
Estimulantes del Sistema Nervioso Central/farmacología , Metilfenidato/farmacología , Pubertad Precoz/genética , Pubertad Precoz/psicología , Conducta Sexual/psicología , Disfunciones Sexuales Psicológicas/tratamiento farmacológico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Preescolar , Humanos , Masculino , Metilfenidato/uso terapéutico , Conducta Sexual/efectos de los fármacos , Resultado del Tratamiento
5.
Neuroscience ; 197: 225-32, 2011 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-21964472

RESUMEN

Major questions remain about the specific role of testosterone in human spatial navigation. We tested 10 boys (mean age 11.65 years) with an extremely rare disorder of androgen excess (Familial Male Precocious Puberty, FMPP) and 40 healthy boys (mean age 12.81 years) on a virtual version of the Morris Water Maze task. In addition, anatomical magnetic resonance images were collected for all patients and a subsample of the controls (n=21) after task completion. Behaviourally, no significant differences were found between both groups. However, in the MRI analyses, grey matter volume (GMV) was correlated with performance using voxel-based morphometry (VBM). Group differences in correlations of performance with GMV were apparent in medial regions of the prefrontal cortex as well as the middle occipital gyrus and the cuneus. By comparison, similar correlations for both groups were found in the inferior parietal lobule. These data provide novel insight into the relation between testosterone and brain development and suggest that morphological differences in a spatial navigation network covary with performance in spatial ability.


Asunto(s)
Andrógenos/metabolismo , Encéfalo/fisiopatología , Aprendizaje por Laberinto/fisiología , Pubertad Precoz/patología , Pubertad Precoz/fisiopatología , Encéfalo/patología , Niño , Humanos , Interpretación de Imagen Asistida por Computador , Imagen por Resonancia Magnética , Masculino , Conducta Espacial/fisiología , Análisis y Desempeño de Tareas , Testosterona/metabolismo
7.
Mol Genet Metab ; 66(1): 68-73, 1999 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9973550

RESUMEN

Familial male-limited precocious puberty (FMPP) is a form of luteinizing hormone-releasing hormone (LHRH)-independent isosexual precocious puberty caused by gain-of-function mutations of the luteinizing hormone/chorionic gonadotropin receptor (hLHR). The most common mutation is 1733 A>G, which causes substitution of Asp-578 by Gly. In this study, a male infant presented at the age of 20 months with accelerated sexual development was analyzed for the presence of activating mutations of the hLHR. Analysis of exon 11 of the hLHR gene by genomic polymerase chain reaction (PCR), asymmetric PCR, and dideoxy sequencing identified a single base substitution, 1734 T>A, which led to the replacement of Asp-578 by Glu. The same mutation was found in the mother. Expression of the mutated hLHR in HEK 293 cells demonstrated elevated basal levels of intracellular cAMP in the transfected cells confirming the constitutive activating nature of the mutated hLHR. A possible genotype-phenotype relationship of the hLHR mutations was examined by a comparison of the in vitro activities of the hLHRs carrying the Asp578Gly, Asp578Tyr, Asp578Trp, and Asp578Glu mutations in HEK 293 cells. A positive correlation between the size of the substituting amino acid and the basal level of intracellular cAMP of cells expressing the mutated receptor was demonstrated.


Asunto(s)
Pubertad Precoz/genética , Receptores de HL/genética , Secuencia de Aminoácidos , Aminoácidos/química , Aminoácidos/genética , Línea Celular , AMP Cíclico/metabolismo , ADN/química , ADN/genética , Análisis Mutacional de ADN , Salud de la Familia , Humanos , Lactante , Masculino , Datos de Secuencia Molecular , Peso Molecular , Mutación , Pubertad Precoz/patología , Receptores de HL/química , Relación Estructura-Actividad , Transfección
8.
J Pediatr ; 138(3): 406-10, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11241051

RESUMEN

OBJECTIVE: To evaluate the effect of growth hormone (GH) therapy on pubertal onset, pubertal pace, adult testicular function, and adrenarche in boys with non-GH-deficient short stature. STUDY DESIGN: Randomized, double-blind, placebo-controlled trial. GH (0.074 mg/kg, subcutaneously, 3 times per week) or placebo treatment was initiated in prepubertal or early pubertal boys and continued until near final height was reached (n = 49). Statistical significance was assessed by survival analysis, repeated-measures analysis of variance, and Student t test. RESULTS: GH therapy did not affect the age at pubertal onset, defined either by testicular volume >4 mL or by testosterone concentration >1.0 nmol/L (30 ng/dL). GH treatment also did not affect the pace of puberty, defined either by the rate of change in testicular volume or testosterone concentration during the 4 years after pubertal onset. In boys followed up to age > or =16 years during the study, there were no significant differences in final testicular volume or in plasma testosterone, luteinizing hormone, or follicle-stimulating hormone concentrations. The pace of adrenarche, assessed by change in dehydroepiandrosterone sulfate levels over time, also did not differ significantly between the GH and placebo groups. CONCLUSION: Our findings suggest that GH treatment does not cause testicular damage, alter the onset or pace of puberty, or alter the pace of adrenarche in boys with non-GH-deficient short stature.


Asunto(s)
Enanismo/tratamiento farmacológico , Hormona de Crecimiento Humana/uso terapéutico , Pubertad/efectos de los fármacos , Testículo/efectos de los fármacos , Adolescente , Edad de Inicio , Análisis de Varianza , Niño , Sulfato de Deshidroepiandrosterona/sangre , Método Doble Ciego , Humanos , Masculino , Análisis de Supervivencia , Testosterona/sangre
9.
J Pediatr ; 138(6): 949-51, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11391350

RESUMEN

In boys with familial male-limited precocious puberty, an activating mutation of the luteinizing hormone receptor causes Leydig cell hyperplasia, resulting in excess testosterone production. There are no reports of Leydig cell masses in boys with familial male-limited precocious puberty. We describe a 10-year-old boy with familial male-limited precocious puberty who developed Leydig cell nodules.


Asunto(s)
Células Intersticiales del Testículo/patología , Pubertad Precoz/genética , Pubertad Precoz/patología , Niño , Humanos , Hiperplasia , Masculino , Pubertad Precoz/metabolismo , Testículo/diagnóstico por imagen , Testosterona/biosíntesis , Ultrasonografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA